65,437 trials
Pancreatic Cancer Non-resectable · Pancreatic Cancer Metastatic
Primary: Disease Control Rate (DCR) at 4 Months Using RECIST 1.1 — 2 Participants
Myocardial Infarction · Heart Failure · Heart Valve Diseases
Primary: Number of CR Sessions Completed Within 6 Months in Patients Randomized to HYCR vs. Patients Randomized to Traditional CBCR (Usual Care). — 28.7; 27.6 Number of cardiac…
Plague, Pneumonic · Plague · Vaccine-Preventable Diseases
Primary: Rates of Reactogenicity and Safety — 16; 67; 57; 0 Participants
Aortic Stenosis · Aortic Valve Stenosis
Primary: Length of Index Hospitalization — 3.3 days
Human Papillomavirus
Primary: Number of Participants Who Completed HPV Vaccine Series — 364; 344 Participants
Stroke · Cerebrovascular Disorders · Brain Diseases
Primary: Fugl-Meyer Assessment (FMA) — 32.5; 32.8 score on a scale
Breast Cancer
Primary: Number of Participants With Oncotype DX Testing Ordered — 92; 62; 50; 74 Participants — p=0.37
Myomectomy; Surgical Blood Loss
Primary: Surgical Blood Loss — 761; 691 ml
Atopic Dermatitis
Primary: Percentage of Participants Who Responded Agree or Strongly Agree to the 'Overall Ease of Use' Question Using the Modified Subcutaneous Administration Assessment…
Adult Attention Deficit Hyperactivity Disorder
Primary: Change in Expanded Adult ADHD Investigator Symptom Rating Scale (AISRS) Total Score — 24.1 score on a scale
Granulosa Cell Ovarian Cancer · Low Grade Serous Ovarian/ Primary Peritoneal Cancer · Endometrioid Endometrial Cancer
Primary: Overall Response Rate — 0; 0; 0; 0 Participants
Major Depressive Disorder
Primary: Change in Depressive Symptoms Measured by the Patient Health Questionnaire (PHQ-9) — 21; 31.5 percentage of change
COVID-19
Primary: Incidence of SARS-CoV-2 Clearance — 34.2; 38.5; 30.3; 27.0 percentage of paticaipants
Obesity, Gliosis, Weight-Loss
Primary: Percent Change in Weight From Baseline — -6.1; -21.2; 1.2 percentage change from baseline — p=<0.001
Healthy
Primary: Urinary and Fecal Excretion of Radioactivity Over Time Expressed as a Percentage of the Total Radioactive Dose Administered — 90.2 percentage of administered radioactivity